A lesson learnt: the rise and fall of Lariam and Halfan.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

22 citing papers in PubMed.

1. Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy.PloS one · 2015
   Trial
2. Malaria Prevention: Progress to Date.Drugs · 2026
   Review
3. Intramolecular Cyclization During Bromination of the Quinoline Alkaloid Haplophyllidine.Chemistry of natural compounds · 2022
   Article
4. Antimalarial Natural Products.Progress in the chemistry of organic natural products · 2022
   Article
5. Mefloquine as a prophylaxis for malaria needs to be revisited.International journal for parasitology. Drugs and drug resistance · 2021
   Review
6. A Cluster ofTropical medicine and infectious disease · 2021
   Article
7. Targeting SHIP1 and SHIP2 in Cancer.Cancers · 2021
   Review
8. Derivatives of the Antimalarial Drug Mefloquine Are Broad-Spectrum Antifungal Molecules with Activity against Drug-Resistant Clinical Isolates.Antimicrobial agents and chemotherapy · 2020
   Article
9. The past, present and future of anti-malarial medicines.Malaria journal · 2019
   Review
10. Activity of mefloquine and mefloquine derivatives against Echinococcus multilocularis.International journal for parasitology. Drugs and drug resistance · 2018
    Article
11. Synthesis and antiplasmodial activity of novel phenanthroline derivatives: AnIranian journal of basic medical sciences · 2018
    Article
12. Prolonged Neuropsychiatric Symptoms in a Military Service Member Exposed to Mefloquine.Drug safety - case reports · 2016
    Article
13. Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives.Malaria journal · 2016
    Review
14. Synthesis and initial evaluation of quinoline-based inhibitors of the SH2-containing inositol 5'-phosphatase (SHIP).Bioorganic & medicinal chemistry letters · 2015
    Article
15. A small-fish model for behavioral-toxicological screening of new antimalarial drugs: a comparison between erythro- and threo-mefloquine.BMC research notes · 2015
    Article
16. Malaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence Force.Journal of parasitology research · 2015
    Review
17. Rational Risk-Benefit Decision-Making in the Setting of Military Mefloquine Policy.Journal of parasitology research · 2015
    Review
18. Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine.International journal for parasitology. Drugs and drug resistance · 2014
    Article
19. Case Study of Small Molecules As Antimalarials: 2-Amino-1-phenylethanol (APE) Derivatives.ACS medicinal chemistry letters · 2014
    Article
20. Mefloquine use, psychosis, and violence: a retinoid toxicity hypothesis.Medical science monitor : international medical journal of experimental and clinical research · 2013
    Article

Corrections and comments

• Commented on by
  Lariam and Halfan.2007

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as